HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) —
- Event will likely be held on October 18-19, 2022 in Boston, MA
- Samuel Wickline, MD, Chief Scientific Officer, to current on the benefits of the OligoPhore/SemaPhore know-how, a flexible peptide-based supply platform for extrahepatic RNA supply
- The occasion will present the Company the chance to current its revolutionary supply platform and have interaction with RNA group in science and business
Altamira Therapeutics Ltd. (Nasdaq: CYTO), an organization devoted to growing therapeutics that tackle necessary unmet medical wants, as we speak introduced that it’ll take part in-person at the RNA Leaders USA Congress being held on October 18-19, 2022 at The Colonnade Hotel in Boston, Massachusetts.
Altamira’s Chief Scientific Officer, Samuel A. Wickline, MD, will likely be introducing the Company’s flagship OligoPhore/ SemaPhore supply platform and tackle the next points and benefits of siRNA therapeutics that differentiate the Company’s know-how:
- Universal formulation course of for any RNA species, single or multiplexed to tackle a number of signaling pathways concurrently
- Systemic administration attaining extrahepatic supply to numerous pathologies, however excluding permeation of regular tissues to restrict off-target results
- Deep penetration into tumor and inflammatory microenvironment
- Extensive and speedy pH-dependent endosomal escape of RNA cargo to promote instant RNA silencing or enhanced protein expression as wanted
- Minimize tissue toxicity and immune reactivity after serial dosing in a multiplicity of illness fashions
- Adaptable to numerous pathologies with readily exchangeable RNA cargos to counter adaptive illness responses
Altamira goals to change into a number one supplier of RNA supply know-how by means of its patented OligoPhore/SemaPhore platform, which it seeks to out-license to biotech and pharma corporations to be used with their very own RNA molecules. In addition, the Company is progressing two inside early-stage applications which make the most of the know-how: the AM-401 program that targets KRAS-driven cancers and the AM-411 program that focuses on the therapy for rheumatoid arthritis. Both applications shall be out-licensed for later growth steps.
About RNA Leaders USA Congress
The RNA Leaders USA Congress focuses on the scientific, scientific and industrial growth of RNA therapeutics and vaccines. The occasion brings collectively probably the most senior executives to ship updates from throughout the complete RNA panorama (RNAi, antisense applied sciences, small molecule focusing on, mRNA and extra).
About OligoPhore/SemaPhore
OligoPhore/SemaPhore is a flexible platform for secure and efficient supply of oligonucleotides equivalent to siRNA (small interfering ribonucleic acid) or mRNA (messenger RNA) into goal cells. It is predicated on a proprietary 21-amino acid peptide that may interact any sort of RNA in speedy self-assembly right into a polyplex. The polyplex has measurement, cost, and different bodily options that permit it to escape hepatic uptake and thus to attain extrahepatic tissues. OligoPhore/SemaPhore protects the RNA payload from degradation within the circulation and permits for speedy mobile uptake, whereas enabling pH-dependent nucleotide endosomal escape and cytoplasmic supply. Effective supply and optimistic therapy outcomes have been demonstrated in additional than 10 murine fashions of illness for targets within the RAS and NF-κB households, the ETS transcription issue household, and targets within the JNK, TAM, and different signaling pathways.
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is devoted to growing therapeutics that tackle necessary unmet medical wants. The Company is at present lively in three areas: the event of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for cover in opposition to airborne allergens and, the place authorized, viruses (Bentrio™; industrial) or for the therapy of vertigo (AM-125; put up Phase 2), and the event of therapeutics for intratympanic therapy of tinnitus or listening to loss (Keyzilen® and Sonsuvi®; Phase 3). Founded in 2003, it’s headquartered in Hamilton, Bermuda, with its fundamental operations in Basel, Switzerland. For extra data, go to: https://altamiratherapeutics.com/
Forward-Looking Statements
This press launch could include statements that represent “forward-looking statements” throughout the which means of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements aside from historic details and will embrace statements that tackle future working, monetary or business efficiency or Altamira Therapeutics’ methods or expectations. In some instances, you possibly can establish these statements by forward-looking phrases equivalent to “may”, “might”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the adverse of those phrases or different comparable terminology. Forward-looking statements are based mostly on administration’s present expectations and beliefs and contain important dangers and uncertainties that would trigger precise outcomes, developments and business choices to differ materially from these contemplated by these statements. These dangers and uncertainties embrace, however aren’t restricted to, the approval and timing of commercialization of AM-301, Altamira Therapeutics’ want for and talent to increase substantial further funding to proceed the event of its product candidates, the timing and conduct of scientific trials of Altamira Therapeutics’ product candidates, the scientific utility of Altamira Therapeutics’ product candidates, the timing or probability of regulatory filings and approvals, Altamira Therapeutics’ mental property place and Altamira Therapeutics’ monetary place, together with the affect of any future acquisitions, tendencies, partnerships, license transactions or modifications to Altamira Therapeutics’ capital construction, together with future securities choices. These dangers and uncertainties additionally embrace, however aren’t restricted to, these described below the caption “Risk Factors” in Altamira Therapeutics’ Annual Report on Form 20-F for the yr ended December 31, 2021, and in Altamira Therapeutics’ different filings with the SEC, which can be found freed from cost on the Securities Exchange Commission’s web site at: www.sec.gov . Should a number of of those dangers or uncertainties materialize, or ought to underlying assumptions show incorrect, precise outcomes could range materially from these indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to individuals appearing on behalf of Altamira Therapeutics are expressly certified of their entirety by reference to these dangers and uncertainties. You shouldn’t place undue reliance on forward-looking statements. Forward-looking statements converse solely as of the date they’re made, and Altamira Therapeutics doesn’t undertake any obligation to replace them in mild of recent data, future developments or in any other case, besides as could also be required below relevant regulation.
